Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy

作者：Duong Vu H; Jaglal Michael V; Zhang Ling; Kale Vishakha; Lancet Jeffrey E; Komrokji Rami S^*; List Alan F

来源：Leukemia Research, 2013, 37(3): 300-304.

DOI：10.1016/j.leukres.2012.11.001

• Myelodysplastic syndromes
• Myelodysplastic-myeloproliferative diseases
• Dasatinib
• Azacitidine
• Decitabine

Given evidence for the role of Src family kinases, especially Lyn kinase, in myeloblast proliferation and the in vitro inhibitory activity of dasatinib on Src and Lyn, we conducted a phase II study to assess overall response to 100 mg/day dasatinib in patients with higher-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia arising from MDS and who had failed prior treatment with azanucleoside analogs. Among 18 patients treated, 3 responded, 4 had stable disease, and 10 experienced disease progression. Toxicities were limited and consistent with previous reports. Dasatinib appears to be safe but with limited efficacy.

• 出版日期2013-3